论文部分内容阅读
1997年10月15日中国医药工业公司为匈牙利吉瑞药厂生产的紧急避孕药“保仕安”(Postinor)进口召开了座谈会。世界卫生组织人类生殖规划处官员Helena von Hertzen博士介绍了WHO组织的紧急避孕多中心随机临床试验的初步结果。该研究在14个国家21个中心进行,比较了左炔诺孕酮(LNG)与经典Yuzpe方案用于紧急避孕。中国有3个中心参加,共接纳500例。给药方案为无保护性生活后72小时内首次给药。随机分为两组:一组给LNG 0.75mg另一组给炔雌醇0.1mg+LNG 0.5mg,两组均于12小时后重复一次同样剂量药物。一共接纳有效病例1955例。
On October 15, 1997, China National Pharmaceutical Industry Corporation held a symposium on the import of Postinor, an emergency contraceptive manufactured by Hungary’s Jiarui Pharmaceutical Factory. Dr. Helena von Hertzen, WHO Officer in the Office of Human Reproductive Planning, presented the preliminary results of the WHO randomized multicenter clinical trial of emergency contraception. The study was conducted in 21 centers in 14 countries and compared levonorgestrel (LNG) with the classic Yuzpe regimen for emergency contraception. China has three centers to participate, a total of 500 accepted. The dosing regimen was first administered within 72 hours of unprotected life. Randomly divided into two groups: one group to LNG 0.75mg another group ethinyl estradiol 0.1mg + LNG 0.5mg, both groups were repeated after 12 hours the same dose of drug. A total of 1955 cases were accepted effective cases.